TR201910251T4 - Kanserin tedavi edilmesine yönelik iyonlaştırıcı radyasyonlar ile kombinasyon halinde hafniyum (ıv) oksidin veya renyum (ıv) oksidin nanopartiküllerini içeren bileşimler. - Google Patents
Kanserin tedavi edilmesine yönelik iyonlaştırıcı radyasyonlar ile kombinasyon halinde hafniyum (ıv) oksidin veya renyum (ıv) oksidin nanopartiküllerini içeren bileşimler. Download PDFInfo
- Publication number
- TR201910251T4 TR201910251T4 TR2019/10251T TR201910251T TR201910251T4 TR 201910251 T4 TR201910251 T4 TR 201910251T4 TR 2019/10251 T TR2019/10251 T TR 2019/10251T TR 201910251 T TR201910251 T TR 201910251T TR 201910251 T4 TR201910251 T4 TR 201910251T4
- Authority
- TR
- Turkey
- Prior art keywords
- oxide
- nanoparticles
- ionizing radiations
- rhenium
- hafnium
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000005865 ionizing radiation Effects 0.000 title abstract 2
- CJNBYAVZURUTKZ-UHFFFAOYSA-N hafnium(iv) oxide Chemical compound O=[Hf]=O CJNBYAVZURUTKZ-UHFFFAOYSA-N 0.000 title 2
- 201000011510 cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- WXBOMIKEWRRKBB-UHFFFAOYSA-N rhenium(iv) oxide Chemical compound O=[Re]=O WXBOMIKEWRRKBB-UHFFFAOYSA-N 0.000 title 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361756533P | 2013-01-25 | 2013-01-25 | |
| EP13305087 | 2013-01-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201910251T4 true TR201910251T4 (tr) | 2019-07-22 |
Family
ID=67296872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/10251T TR201910251T4 (tr) | 2013-01-25 | 2014-01-24 | Kanserin tedavi edilmesine yönelik iyonlaştırıcı radyasyonlar ile kombinasyon halinde hafniyum (ıv) oksidin veya renyum (ıv) oksidin nanopartiküllerini içeren bileşimler. |
Country Status (9)
| Country | Link |
|---|---|
| DK (1) | DK2948179T3 (es) |
| ES (1) | ES2734493T3 (es) |
| HR (1) | HRP20191272T1 (es) |
| HU (1) | HUE045407T2 (es) |
| LT (1) | LT2948179T (es) |
| NZ (2) | NZ709685A (es) |
| PT (1) | PT2948179T (es) |
| SG (1) | SG10202105500VA (es) |
| TR (1) | TR201910251T4 (es) |
-
2014
- 2014-01-24 PT PT14701965T patent/PT2948179T/pt unknown
- 2014-01-24 NZ NZ70968514A patent/NZ709685A/en unknown
- 2014-01-24 ES ES14701965T patent/ES2734493T3/es active Active
- 2014-01-24 NZ NZ750194A patent/NZ750194A/en unknown
- 2014-01-24 SG SG10202105500VA patent/SG10202105500VA/en unknown
- 2014-01-24 HU HUE14701965A patent/HUE045407T2/hu unknown
- 2014-01-24 TR TR2019/10251T patent/TR201910251T4/tr unknown
- 2014-01-24 DK DK14701965.7T patent/DK2948179T3/da active
- 2014-01-24 LT LTEP14701965.7T patent/LT2948179T/lt unknown
-
2019
- 2019-07-16 HR HRP20191272TT patent/HRP20191272T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ709685A (en) | 2019-10-25 |
| HUE045407T2 (hu) | 2019-12-30 |
| HRP20191272T1 (hr) | 2019-10-18 |
| LT2948179T (lt) | 2019-08-12 |
| SG10202105500VA (en) | 2021-07-29 |
| DK2948179T3 (da) | 2019-07-22 |
| PT2948179T (pt) | 2019-07-19 |
| NZ750194A (en) | 2020-02-28 |
| ES2734493T3 (es) | 2019-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121838T1 (el) | Συνθεσεις που περιλαμβανουν νανοσωματιδια οξειδιου του αφνιου (iv) ή οξειδιου του ρηνιου (iv) σε συνδυασμο με ιονιζουσες ακτινοβολιες για αντιμετωπιση καρκινου | |
| CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
| CY1122186T1 (el) | Μεθοδοι θεραπειας καρκινου | |
| BR112015011830A2 (pt) | compostos e seus métodos de utilização | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| BR112016006978A2 (pt) | inibidores de tirosina quinase de bruton | |
| PH12015501552A1 (en) | Androgen receptor modulator and uses thereof | |
| WO2015009726A3 (en) | Medical uses of cd38 agonists | |
| BR112015023910A2 (pt) | terapia envolvendo anticorpos contra claudin 18.2 para tratamento de câncer | |
| MX2019010601A (es) | Terapia de combinacion para tratar cancer. | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| BR112015019995A2 (pt) | Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer | |
| BR112015011171A2 (pt) | compostos de pirrolopirimidina como inibidores da quinase | |
| BR112015029386A2 (pt) | uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer | |
| EA201591925A1 (ru) | Терапевтические композиции и их применение | |
| CR20120508A (es) | PROTEÍNA DE FUSIÓN ROBO1-Fc Y SU UTILIZACIÓN EN EL TRATAMIENTO DE TUMORES | |
| BR112015026257A2 (pt) | terapia de combinação compreendendo um composto di-hidropirazino-pirazina e um antagonista do receptor de andrógeno para tratar câncer de próstata | |
| TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
| TR201811308T4 (tr) | Kanser kok hücrelerini azaltan anti-emp2 tedavisi. | |
| EP3581653A3 (en) | Methods and compositions for treating cancer using peptide nucleic acid-based agents | |
| TR201910251T4 (tr) | Kanserin tedavi edilmesine yönelik iyonlaştırıcı radyasyonlar ile kombinasyon halinde hafniyum (ıv) oksidin veya renyum (ıv) oksidin nanopartiküllerini içeren bileşimler. | |
| MX2017013668A (es) | Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer. | |
| EA201790640A1 (ru) | Средство, обладающее противоклоногенной активностью в отношении опухолевых клеток человека |